By capitalizing upon the reversibility of glycosyltransferase-catalyzed reactions, EryBV was characterized in vitro as the erythromycin mycarosyltransferase and the EryBV substrate specificity was investigated. Two-GT (EryBV/AveBI) aglycon-exchange reactions also led to the production of novel hybrid “erythromycin–avermectin” macrolides.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: